Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00645
|
|||||
| Drug Name |
Carnosine
|
|||||
| Synonyms |
L-carnosine; beta-alanyl-L-histidine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Schizophrenia [ICD11:6A20] | Phase 2/3 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H14N4O3
|
|||||
| Canonical SMILES |
C1=C(NC=N1)CC(C(=O)O)NC(=O)CCN
|
|||||
| InChI |
InChI=1S/C9H14N4O3/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6/h4-5,7H,1-3,10H2,(H,11,12)(H,13,14)(H,15,16)/t7-/m0/s1
|
|||||
| InChIKey |
CQOVPNPJLQNMDC-ZETCQYMHSA-N
|
|||||
| CAS Number |
CAS 305-84-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 226.23 | Topological Polar Surface Area | 121 | ||
| Heavy Atom Count | 16 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
-4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10298255
,103529382
,104619952
,11113307
,11341645
,11361828
,11364072
,11366634
,11369196
,11372223
,11375363
,11377358
,11484264
,11487230
,11488270
,11491027
,11493487
,11494992
,11537748
,117531262
,118260670
,124558660
,124636547
,124883182
,126522966
,126608870
,126622085
,126623164
,126653762
,15121551
,15121552
,15196090
,15220561
,24893178
,26612130
,26679654
,26754272
,3138777
,3676
,36883477
,47574407
,48095570
,49747061
,53837760
,74607942
,8143363
,85165054
,87561884
,88835064
,92715522
|
|||||
| ChEBI ID |
CHEBI:15727
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT02686697) Carnosine and Cognitive Training in Schizophrenia | |||||
| 2 | Transforming dietary peptides in promising lead compounds: the case of bioavailable carnosine analogs. Amino Acids. 2012 Jul;43(1):111-26. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.